hempa has been researched along with Diabetes Mellitus, Type 2 in 1 studies
*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Gao, W; Li, K; Li, M; Liu, H; Liu, Y; Qin, Y; Sun, T; Tang, Y; Tao, H; Yang, C; Yang, J; Yang, L | 1 |
1 other study(ies) available for hempa and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Potential type 2 diabetes mellitus drug HMPA promotes short-chain fatty acid production by improving carbon catabolite repression effect of gut microbiota.
Topics: Catabolite Repression; Diabetes Mellitus, Type 2; Fatty Acids, Volatile; Gastrointestinal Microbiome; Hempa; Humans; Pharmaceutical Preparations; RNA, Ribosomal, 16S | 2021 |